

FORM PTO-1449 Approved for use through 10/31/2002 <div style="border: 1px solid black; border-radius: 50%; padding: 5px; display: inline-block; transform: rotate(-45deg); transform-origin: center;"> MAY 22 2002 PATENT & TRADEMARK OFFICE </div>		US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Attorney's Docket No. AMI-011-RC2		Serial No. 10/015,534	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant Burton G. Christensen et al.		Filing Date December 13, 2001	
				Group Art Unit 1627			

U.S. PATENT DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
<i>MS</i>	A1	*4,587,046		Goodman et al.			
<i>MS</i>	A2	*5,463,564		Agrafiotis et al.			
<i>MS</i>	A3	*5,607,921		Bernard et al.			
<i>MS</i>	A4	5,891,643		Fesik et al.			
<i>MS</i>	A5	*5,962,701		Rosenau et al.			


FOREIGN PATENT DOCUMENTS								
Examiner Initial	Ref. No.	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<i>MS</i>	B1	*97/00244		WIPO				
<i>MS</i>	B2	*98/02186		WIPO				
<i>MS</i>	B3	98/16536		WIPO				
<i>MS</i>	B4	98/16638		WIPO				
<i>MS</i>	B5	*0306904		EPO				
<i>MS</i>	B6	*0433043		EPO				
<i>MS</i>	B7	0825191		EPO				None
<i>MS</i>	B8	2317173		GB				
<i>MS</i>	B9	62-164609		JP				None

(including English-language abstract)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
<i>MS</i>	C1	*Adham et al., Naunyn-Schmiedeberg's Arch. Pharmacol. 348:556-575 (1993)
<i>MS</i>	C2	*Adham et al., Neuropharmacol. 36(4/5):569-576 (1997)
<i>MS</i>	C3	*Alabaster, Life Sci. 60(13/14):1053-1060 (1997)
<i>MS</i>	C4	*Bartow et al., Drugs 55(2):303-322 (1998)
<i>MS</i>	C5	*Beer et al., Br. J. Pharmacol. 110:1196-1200 (1993)
<i>MS</i>	C6	*Bergendal et al., Br. J. Pharmacol. 117:1009-1015 (1996)
<i>MS</i>	C7	*Bergsma et al., Biochem. Biophys. Res. Comm. 183:989-995 (1992)
<i>MS</i>	C8	*Boulet, Drugs 47(2):207-222 (1994)

EXAMINER <i>MS</i>	DATE CONSIDERED <i>9/24/04</i>
--------------------	--------------------------------

EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to applicant.

FORM PTO 1449 Approved for use through 10/31/2002 INFORMATION DISCLOSURE CITATION MAY 22 2002 (Use several sheets if necessary)		US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Attorney's Docket No. AMI-011-RC2	Serial No. 10/015,534
				Applicant Burton G. Christensen et al.	
				Filing Date December 13, 2001	Group Art Unit 1627
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)					
ms	C9	*Buckley et al., Mol. Pharmacol. 35:469-476 (1989)			
ms	C10	*Burnier et al., Exp. Opin. Invest. Drug 6(5):489-500 (1997)			
ms	C11	*Carini et al., J. Med. Chem. 34(8):2525-2547 (1991)			
ms	C12	*Carini et al., J. Med. Chem. 33(5):1330-1336 (1990)			
ms	C13	*Casas et al., J. Drugs Future 22(5):481-491 (1997)			
ms	C14	*Chiu et al., JPET 252(2):711-718 (1990)			
ms	C15	*Cvejic et al., J. Biol. Chem. 272(43):26959-26964 (1997)			
ms	C16	*Dixon et al., Nature 321:75-79 (1986)			
ms	C17	*Duncia et al., J. Med. Chem. 33(5):1312-1329 (1990)			
ms	C18	*Dzielak, Exp. Opin. Invest. Drugs 7(5):741-751 (1998)			
ms	C19	*Eglen et al., DNP 10(8):462-469 (1997)			
ms	C20	*Eglen et al., Pharmacol. Toxicol. 78:59-68 (1996)			
ms	C21	*Ferro et al., Br. J. Clinical. Pharmacol. 40:245-251 (1995)			
ms	C22	*Fiorelli et al., J. Steroid. Biochem. Mol. Biol. 59(2):233-240 (1996)			
ms	C23	*Gardiner, Exp. Opin. Invest. Drug 7(3):405-411 (1998)			
ms	C24	*Garssen et al., Br. J. Pharmacol. 109:53-60 (1993)			
ms	C25	*George, J. Neurochem. 69(3):1278-1285 (1997)			
ms	C26	*Goadsby et al., Headaches 34:394-399 (1994)			
ms	C27	*Goadsby, "Animal models of migraine: which model, why and for what"? <i>Migraine and Headache Pathophysiology</i> , Chap. 14, Ed. L. Edvinsson, Martin Dunitz Ltd., London 1999			
ms	C28	*Green et al., J. Biol. Chem. 271(39):24029-24035 (1996)			
ms	C29	*Green et al., Mol. Pharmacol. 41:889-893 (1992)			
ms	C30	*Green et al., J. Biol. Chem. 269(42):26215-26219 (1994)			
ms	C31	*Hamel et al., Mol. Pharmacol. 44:242-246 (1993)			
ms	C32	*Heavner, DDT 1(7):295-304 (1996)			
ms	C33	*Hebert et al., J. Biol. Chem. 271(27):16384-16392 (1996)			
ms	C34	*Hebert et al., Biochem. Cell Biol. 76(1):1-11 (1998)			
ms	C35	*Holzgrave et al., DDT 3(5):214-222 (1998)			
ms	C36	*Janssen, Drug Invest. 3(Suppl 1):1-2 (1991)			
ms	C37	*Kahne, Curr. Opin. Chem. Biol. 1(1):130-135 (1997)			
EXAMINER					
		DATE CONSIDERED <i>9/24/01</i>			
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449 Approved for use through 10/31/2002 INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Attorney's Docket No. AMI-011-RC2	Serial No. 10/105534
				Applicant Burton G. Christensen et al.	
				Filing Date December 13, 2001	Group Art Unit 1627
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)					
	C38	*Kobilka et al., Nature 329:75-79 (1987)			
<i>ms</i>	C39	*Kretzschmar et al., Tet. Lett. 51(47):13015-13030 (1995)			
<i>ms</i>	C40	*Kukkonen et al., J. Pharmacol. Exp. Ther. 279(2):593-601 (1996)			
<i>ms</i>	C41	*Kukkonen et al., Biochem. Biophys. Res. Comm. 243(1):41-46 (1998)			
<i>ms</i>	C42	*Leboulluec et al., Bioorg. Med. Chem. Lett. 5(2):123-126 (1995)			
<i>ms</i>	C43	*Lee et al., Mol. Pharmacol. 50:140-148 (1996)			
<i>ms</i>	C44	*Liang et al., Science 274:1520-1522 (1996)			
<i>ms</i>	C45	*Liggett et al., Mol. Pharmacol. 36:641-646 (1989)			
<i>ms</i>	C46	*Lofdahl et al., Asthma 2:1523-1533 (1997)			
<i>ms</i>	C47	*Longmore et al., Br. J. Clin. Pharmacol. 42:431-441 (1996)			
<i>ms</i>	C48	*McClellan et al., Drugs 55(5):713-718 (1998)			
<i>ms</i>	C49	*McCrea et al., Br. J. Pharmacol. 110:619-626 (1993)			
<i>ms</i>	C50	*MacLagan et al., TIPS (Suppl):88-92 (1989)			
<i>ms</i>	C51	*Maggio et al., PNAS 90:3103-3107(1993)			
<i>ms</i>	C52	*Martel et al., Drugs Future 22(2):135-137 (1997)			
<i>ms</i>	C53	*Martin et al., Br. J. Pharmacol. 121:157-164 (1997)			
<i>ms</i>	C54	*Merlos et al., Drugs Future 22(8):850-855 (1997)			
<i>ms</i>	C55	*Monnot et al., J. Biol. Chem. 271(3):1507-1513 (1996)			
<i>ms</i>	C56	*Mukoyama et al., J. Biol. Chem. 268(33):24539-24542 (1993)			
<i>ms</i>	C57	*Nials et al., Br. J. Pharmacol. 110:1112-1116 (1993)			
<i>ms</i>	C58	*Nials et al., Eur. J. Pharmacol. 251:127-135 (1994)			
<i>ms</i>	C59	*Nikko/Masato et al., Chem Abstract 113(2):354 #11917g (1990)			
<i>ms</i>	C60	*Nimchinsky et al., J. Biol. Chem. 272(46):29229-29237 (1997)			
<i>ms</i>	C61	*Ngo et al., Drugs Future 22(3):260-269 (1997)			
<i>ms</i>	C62	*Pauwels et al., Biochem. Pharmacol. 45(2):375-383 (1993)			
<i>ms</i>	C63	*Pauwels et al., Naunyn-Schmiedeberg's Arch. Pharmacol. 353:144-156 (1996)			
<i>ms</i>	C64	*Piergentili et al. II Farmaco 49(2):83-87 (1994)			
<i>ms</i>	C65	*Portoghese, J. Med. Chem. 35(11):1927-1937 (1992)			
<i>ms</i>	C66	*Rivero et al., Bioorg. Med. Chem. Lett. 3(4):557-560 (1993)			
<i>ms</i>	C67	*Ruffolo et al., J. Med Chem. 38(19):3681-3716 (1995)			
EXAMINER		DATE CONSIDERED			
<i>ms</i>		<i>9/12/04</i>			
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		US DEPARTMENT OF COMMERCE		Attorney's Docket No.		Serial No.	
Approved for use through 10/31/2002		US Patent and Trademark Office		AMI-011-RC2		10/015,534	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant			
				Burton G. Christensen et al.			
				Filing Date		Group Art Unit	
				December 13, 2001		1627	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
ms	C68	*Schoeffter et al., Naunyn-Schmiedeberg's Arch. Pharmacol. 340:135-138 (1989)					
ms	C69	*Shuker et al., Science 274:1531-1534 (1996)					
ms	C70	*Suh et al., Bioorg. Med. Chem. Lett. 7(4):389-392 (1997)					
ms	C71	*Valentin et al., Br. J. Pharmacol. 119:35-42 (1996)					
ms	C72	*Van de Water et al., Eur. J. Pharmacol. 299:127-137 (1996)					
ms	C73	*Veldman et al., Mol. Pharmacol. 42:439-444 (1992)					
ms	C74	*Waldeck et al., Eur. J. Pharmacol. 112(3):349-353 (1985)					
ms	C75	*Waldeck et al., Acta Pharmacol. Toxicol. 58:209-218 (1986)					
ms	C76	*Wexler et al., J. Med. Chem. 39(3):625-656 (1996)					
ms	C77	*Wong et al., JPET 252(2):719-725 (1990)					
ms	C78	*Wong et al., JPET 252(2):726-732 (1990)					
ms	C79	*Wurch et al., Br. J. Pharmacol. 120:153-159 (1997)					
ms	C80	*Yocca, Cephalagia 15(Suppl 14):174- (1995)					
ms	C81	*Zakon, Trends Neurosci. 21:202-207 (1998)					
ms	C82	*Zeng et al., J. Chrom. A 794:3-13 (1998)					
ms	C83	*Zgombick et al., Naunyn-Schmiedeberg's Arch. Pharmacol. 54:226-236 (1996)					
	C84						
	C85						
	C86						
	C87						
	C88						
	C89						
	C90						
	C91						
	C92						
	C93						
	C94						
	C95						
	C96						
	C97						
EXAMINER <i>[Signature]</i>				DATE CONSIDERED 9/29/04			
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							